DC
RVMD icon

Diametric Capital’s Revolution Medicines RVMD Stock Holding History

Diametric Capital’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-15,000
Closed -$1.46M – 656
2026
Q1 		$1.46M Buy
+15,000
New +$1.51M 0.38% 58
2025
Q3 		– Sell
-12,225
Closed -$450K – 466
2025
Q2 		$450K Buy
+12,225
New +$470K 0.24% 116

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Diametric Capital's RVMD Position: Q2 2026 in Review

Diametric Capital sold out of Revolution Medicines (RVMD) in Q2 2026, closing a stake of 15,000 shares — an estimated $1.46M sold.

Diametric Capital first reported a position in RVMD in Q2 2025 and held it in 2 quarters. The position peaked at $1.46M in Q1 2026. 688 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Diametric Capital reported no remaining Revolution Medicines position as of Q2 2026 after selling out during the quarter.
  • Diametric Capital sold 15,000 Revolution Medicines shares in Q2 2026, an estimated $1.46M.
  • Diametric Capital first reported a position in Revolution Medicines in Q2 2025 and held it in 2 quarters.
  • Diametric Capital's Revolution Medicines position peaked at $1.46M in Q1 2026.
  • 688 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Diametric Capital's 13F filing for Q2 2026, filed 14 Aug 2026.